Clinical Trials Browser

Interventional × AFM13 × Clear all

NCT04074746 2025-09-30

Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas

Phase 1/2 Completed

Mycosis Fungoides, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic

NCT05883449 2025-08-20

LuminICE-203

Phase 2 Terminated

25 enrolled 21 charts

Hodgkin Disease, Recurrence, Lymphoma, T-Cell, Peripheral

NCT04101331 2024-11-05

REDIRECT

Phase 2 Completed

108 enrolled 24 charts

Lymphoma, T-Cell, Peripheral

NCT03192202 2023-07-20

AFM13 in Relapsed/Refractory Cutaneous Lymphomas

Phase 1/2 Completed

18 enrolled 9 charts

DermatologicLymphoid

Lymphoma, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

NCT02321592 2020-11-13

GHSG-AFM13

Phase 2 Completed

Hodgkin Disease

NCT02665650 2019-05-16

Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Phase 1 Completed

Hodgkin Disease